Related Experiment Video
Updated: Jun 27, 2025
Preparation of Exosomes for siRNA Delivery to Cancer Cells
Published on: December 5, 2018
Patient-Derived Exosomes as siRNA Carriers in Ovarian Cancer Treatment
Aasa Shimizu1,2, Kenjiro Sawada1, Masaki Kobayashi1
1Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita 565-0871, Japan.
Abstract:
RNA interference is a powerful gene-silencing tool with potential clinical applications. However, its therapeutic use is challenging because suitable carriers are unavailable. Exosomes are stable small endogenous vesicles that can transport functional molecules to target cells, making them ideal small interfering RNA (siRNA) carriers. Herein, we elucidated the therapeutic potential of patient-derived exosomes as an siRNA carrier for ovarian cancer (OC) treatment. The exosomes were extracted from the culture medium of primary fibroblasts collected from the omentum of patients with OC during surgery. MET proto-oncogene, receptor tyrosine kinase (MET) was selected for gene silencing, c-Met siRNAs were synthesized and loaded into the exosomes (Met-siExosomes) via electroporation, and the treatment effect of the Met-siExosomes was assessed in vitro and in vivo. The Met-siExosomes downregulated the c-Met protein levels and inhibited OC cell proliferation, migration, and invasion. In xenograft experiments using SKOV3-13 and ES-2 cells, Met-siExosomes were selectively extracted from peritoneally disseminated tumors. Intraperitoneal treatment suppressed the c-Met downstream targets in cancer cells and prolonged mouse survival. The synthesized siRNAs were successfully and selectively delivered via the exosomes to intraperitoneally disseminated tumors. As patients with OC routinely undergo omentectomy and abundant fibroblasts can be easily collected from the omentum, patient-derived exosomes may represent a promising therapeutic siRNA carrier to treat OC.
Insights
Patient-derived exosomes effectively deliver small interfering RNA (siRNA) to ovarian cancer cells, inhibiting tumor growth and improving survival. This offers a promising new carrier for ovarian cancer (OC) gene silencing therapies.
Area of Science:
- Biomedical Engineering
- Oncology
- Molecular Biology
Background:
- RNA interference (RNAi) is a potent gene-silencing mechanism with therapeutic potential.
- Clinical application of RNAi is hindered by the lack of effective delivery vehicles.
- Exosomes, small endogenous vesicles, show promise as natural carriers for therapeutic molecules like small interfering RNA (siRNA).
Purpose of the Study:
- To investigate the therapeutic efficacy of patient-derived exosomes as carriers for siRNA targeting ovarian cancer (OC).
- To evaluate the potential of using exosomes from patient fibroblasts for OC treatment.
Main Methods:
- Exosomes were isolated from fibroblasts of ovarian cancer patients.
- Small interfering RNA (siRNA) targeting the MET proto-oncogene (c-Met) was synthesized and loaded into exosomes via electroporation, creating Met-siExosomes.
- In vitro and in vivo experiments were conducted using OC cell lines and xenograft models.
Main Results:
- Met-siExosomes successfully downregulated c-Met protein levels in OC cells.
- Treatment with Met-siExosomes inhibited OC cell proliferation, migration, and invasion in vitro.
- In vivo, Met-siExosomes selectively targeted intraperitoneally disseminated tumors, suppressed c-Met downstream targets, and prolonged mouse survival.
Conclusions:
- Patient-derived exosomes are effective carriers for delivering siRNA to ovarian cancer.
- Met-siExosomes demonstrate significant therapeutic potential for ovarian cancer treatment.
- This approach offers a promising, patient-specific strategy for ovarian cancer gene therapy delivery.
